SEC Company Response from Tvardi Therapeutics, Inc. (TVRD) (CIK 0001346830) (TVRD) — Mar 23, 2017
Tvardi Therapeutics, Inc. (TVRD) (CIK 0001346830)
Date: March 23, 2017 · CIK: 0001346830 · Accession: 0001193125-17-093663
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-216657
Letter
Via EDGAR Division of Corporation Finance File No. 333-216657 Acceleration Request Requested Date: Friday, March 24, 2017 Requested Time: 4:00 P.M. Eastern Daylight Time
Dear Ms. Hayes:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-216657) (the “Registration Statement”) to become effective on March 24, 2017, at 4:00 p.m. Eastern Daylight Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Darren DeStefano of Cooley LLP, counsel to the Registrant, at (703) 456-8034, or in his absence, Alison Haggerty at (212) 479-6596.
Very truly yours,
Cara Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request March 23, 2017 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Suzanne Hayes Re: Cara Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-216657 Acceleration Request Requested Date: Friday, March 24, 2017 Requested Time: 4:00 P.M. Eastern Daylight Time Dear Ms. Hayes: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-216657) (the “Registration Statement”) to become effective on March 24, 2017, at 4:00 p.m. Eastern Daylight Time, or as soon thereafter as is practicable. Once the Registration Statement has been declared effective, please orally confirm that event with Darren DeStefano of Cooley LLP, counsel to the Registrant, at (703) 456-8034, or in his absence, Alison Haggerty at (212) 479-6596. Very truly yours, Cara Therapeutics, Inc. By: /s/ Josef Schoell Josef Schoell Chief Financial Officer cc: Derek Chalmers, Ph.D., D.Sc., Cara Therapeutics, Inc. Darren K. DeStefano, Cooley LLP Alison A. Haggerty, Cooley LLP